Literature DB >> 10485446

On the prevention and therapy of prostate cancer by androgen administration.

R T Prehn1.   

Abstract

It has been widely suggested that elevated androgen levels may be critically involved in the genesis of prostate cancer. Despite the dependency of the normal prostate and of most prostatic cancers upon androgens and the fact that tumors can be produced in some rodent models by androgen administration, I will argue that, contrary to prevalent opinion, declining rather than high levels of androgens probably contribute more to human prostate carcinogenesis and that androgen supplementation would probably lower the incidence of the disease. I will also consider the possibility that the growth of androgen-independent prostate cancers might be reduced by the administration of androgens.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10485446

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  23 in total

Review 1.  Differential growth: from carcinogenesis to liver repopulation.

Authors:  E Laconi
Journal:  Am J Pathol       Date:  2000-02       Impact factor: 4.307

2.  Signaling through estrogen receptors modulates telomerase activity in human prostate cancer.

Authors:  Simona Nanni; Michela Narducci; Linda Della Pietra; Fabiola Moretti; Annalisa Grasselli; Piero De Carli; Ada Sacchi; Alfredo Pontecorvi; Antonella Farsetti
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

Review 3.  The Role of Testosterone in the Treatment of Castration-Resistant Prostate Cancer.

Authors:  Michael W Drazer; Walter M Stadler
Journal:  Cancer J       Date:  2016 Sep/Oct       Impact factor: 3.360

4.  Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.

Authors:  H K Lin; S Yeh; H Y Kang; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

5.  Testosterone as a predictor of pathological stage in clinically localized prostate cancer.

Authors:  Ginger Isom-Batz; Fernando J Bianco; Michael W Kattan; John P Mulhall; Hans Lilja; James A Eastham
Journal:  J Urol       Date:  2005-06       Impact factor: 7.450

Review 6.  Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Authors:  A M Traish; A Morgentaler
Journal:  Br J Cancer       Date:  2009-11-03       Impact factor: 7.640

7.  The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.

Authors:  Steffen E Eikenberry; John D Nagy; Yang Kuang
Journal:  Biol Direct       Date:  2010-04-20       Impact factor: 4.540

8.  A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer.

Authors:  Russell Szmulewitz; Supriya Mohile; Edwin Posadas; Rangesh Kunnavakkam; Theodore Karrison; Elizabeth Manchen; Walter M Stadler
Journal:  Eur Urol       Date:  2009-02-27       Impact factor: 20.096

9.  Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Authors:  Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones
Journal:  J Mol Endocrinol       Date:  2013-06-29       Impact factor: 5.098

Review 10.  Killing tumours by ceramide-induced apoptosis: a critique of available drugs.

Authors:  Norman S Radin
Journal:  Biochem J       Date:  2003-04-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.